Andreas Ohlmann
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Articles (10)
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Proliferative vitreoretinopathy (PVR) as a rare fibrotic ocular disease is the main reason for failure of retinal detachment surgery and a reduced prognosis following surgery. Amniotic membrane (AM) is a versatile surgical tool for tissue stabilization, antifibrotic properties, and regeneration. Initial clinical case studies now demonstrated intravitreal tolerance as well as good anatomical and functional results for degenerative retinal diseases. Due to its diverse wound healing properties, AM could have promoting, suppressive, or no effects on PVR. To illuminate the potential of epiretinal AM transplantation in complex retinal detachment cases, we investigated its influence on human primary PVR (hPVR) cells in vitro. In our cell culture study, hPVR cells were isolated from surgically removed PVR membranes. Following incubation with AM for 48 h, AM-incubated hPVR showed significantly reduced proliferation (BrdU-ELISA; p < 0.001 ), migration (Boyden chamber, scratch assay; p = 0.003 and p < 0.001 ), and cell adhesion ( p = 0.005). Collagen contraction was nearly unaffected ( p = 0.04), and toxicity (histone-complexed DNA ELISA, WST-1 assay, and life/dead staining) was excluded. Next, immunofluorescence showed a myofibroblastic phenotype with reduced expression of fibrosis markers in AM-incubated cells, which was confirmed by Western blot analysis. In the proteomics assay, AM significantly regulated proteins by a more than 2-fold increase in expression which were related to the cytoskeleton, lipid metabolism, cell-matrix contraction, and protein folding. In conclusion, this in vitro work suggests no induction of fibrosis and other key steps in the pathogenesis of PVR through AM but rather inhibiting properties of profibrotic cell behavior, making it a possible candidate for suppression of PVR. Further clinical studies are necessary to evaluate the therapeutic relevance.
Year:
2023
Year:
2022
Year:
2022
Year:
2021
Year:
2020
Year:
2020
Collaborators (6)
Arie Geerlof
Head of Protein Expression and Purification Facility
Helmholtz Zentrum München Deutsches Forschungszentrum für Umwelt und Gesundheit
Claudia Priglinger
Prof. Dr. med.
University Hospital, LMU Munich
Daniela Hartmann
Head of Dermatosurgery/Assoc. Prof. MD Ph.D.
University Hospital, LMU Munich
Armin Wolf
Ulm University
Miriam Breunig
University of Regensburg
Danila Boytsov
Medical University of Vienna
Make your next move.
Prepare your application
Review drafts before you send them.